BRLI - Bio-Reference Laboratories Inc.

Bio-Reference Laboratories Inc. (BRLI) is a clinical laboratory testing company that provides laboratory testing services to healthcare providers, patients, and other clinical laboratories throughout the United States. The company offers a wide range of laboratory testing services, including blood testing, molecular testing, and pathology services.

As of its last market close, BRLI had a market capitalization of approximately $1.4 billion USD. The company had a trailing twelve-month revenue of approximately $831 million USD and a net income of approximately $41 million USD. BRLI's stock price had a 52-week range of $14.60 - $45.43 USD and was trading at approximately $43.32 USD at the time of its last market close.

Bio-Reference Laboratories is focused on expanding its reach and growing its market share through the development of new testing services and partnerships with healthcare providers. The company is also committed to enhancing its operational efficiency and improving its financial performance.

Investing in BRLI carries risks, including risks associated with changes in economic conditions and healthcare industry trends, as well as risks associated with changes in government regulations and reimbursement rates. Additionally, Bio-Reference Laboratories is subject to competitive and technological risks, including risks associated with advances in medical technology and competition from larger healthcare providers. Investors should carefully consider these risks before making any investment decisions.

Stock Sector: Health Services: Medical Laboratories & Research